Nervous System & Special Senses

Persistent vegetative state vs minimally conscious state

Clinical Overview and When to Suspect Disorders of Consciousness

— Coma: no eye opening, no sleep-wake cycles, no awareness; typically <2–4 weeks before evolving

— Vegetative state (VS) / unresponsive wakefulness syndrome (UWS): eyes open, sleep-wake cycles preserved, but no reproducible purposeful behavior

— Minimally conscious state (MCS): inconsistent but reproducible evidence of awareness

— Emergence from MCS (eMCS): functional communication or object use

— Patient is >2–4 weeks post severe TBI, anoxic injury (e.g., post–cardiac arrest), large stroke, or hypoxic-ischemic encephalopathy

— Eyes open spontaneously but no command-following on bedside exam

— Family reports "he looked at me" or "she squeezed my hand" — must trigger formal serial assessment for MCS

— Traumatic (TBI from MVC, falls, assaults) — better prognosis

— Non-traumatic anoxic (cardiac arrest, drowning, strangulation) — worst prognosis, especially if absent N20 on SSEPs or myoclonic status

— Massive ICH, bilateral thalamic infarct, fulminant meningoencephalitis, prolonged hypoglycemia

Board pearl: If a "vegetative" patient demonstrates any reproducible visual pursuit, localization to noxious stimuli, or contingent emotional response, the correct diagnosis is MCS, not VS — and prognosis and management diverge sharply. Do not call a patient "vegetative" before formal repeated assessment.

Disorders of consciousness (DoC) are chronic states of impaired awareness following severe brain injury, defined by dissociation between wakefulness (eye opening, sleep-wake cycles) and awareness (responsiveness to self/environment).

Spectrum from most to least impaired:

When to suspect a DoC diagnosis rather than coma or delirium:

Etiologies (Step 3 favorites):

Epidemiology: ~4,200–7,500 new VS cases/yr in US; misdiagnosis rate ~40% when relying on informal bedside exam alone — formal scales (CRS-R) cut this dramatically.

Presentation Patterns and Key History

— Day 0: severe brain insult → coma (eyes closed, GCS ≤8)

— Days 7–28: emergence of sleep-wake cycles with eye opening → VS/UWS

— Variable: appearance of inconsistent purposeful behaviors → MCS

— Recovery of functional communication or object use → emergence from MCS

— Mechanism and timing of injury (TBI vs anoxic vs vascular) — single biggest prognostic variable

— Initial GCS, duration of coma, duration of post-traumatic amnesia

— Imaging at presentation: diffuse axonal injury, bilateral thalamic damage, brainstem sparing

— Hospital course: seizures, ICP crises, hypotension, repeat anoxic events

— Sedation history — midazolam, opioids, baclofen can mimic or deepen DoC for days–weeks; always review the med list before declaring VS

— Tracks people across the room with eyes (visual pursuit — earliest MCS sign)

— Cries when family enters, smiles to specific voices (contingent emotional response)

— Tries to grab the suction tubing or pulls at gown (automatic motor response)

— Inconsistent "yes/no" with blinks or thumb

— Locked-in syndrome (preserved awareness, vertical eye movements only) — basilar/pontine stroke

— Akinetic mutism (frontal/cingulate lesion, hydrocephalus)

— Catatonia or severe depression mimicking unresponsiveness

— Nonconvulsive status epilepticus

Step 3 management: Before diagnosing VS or MCS, (1) stop or wean sedating drugs, (2) treat metabolic derangements and NCSE (EEG), (3) optimize sleep-wake, and (4) repeat formal assessments across multiple days and times of day — a single bedside exam is insufficient and a frequent malpractice pitfall.

Typical timeline the exam tests:

Key historical elements to elicit (often from family in CCS-style stem):

Family-reported behaviors to probe (these distinguish VS from MCS):

Red flags for misdiagnosis:

Physical Exam Findings and Standardized Assessment

— Spontaneous eye opening, preserved sleep-wake cycles

— Reflexive movements only: grasp reflex, chewing, roving eye movements without fixation

— Generalized withdrawal or posturing to noxious stimuli (not localization)

— Brainstem reflexes intact: pupillary, corneal, gag, cough

— May yawn, grimace, even vocalize — but non-purposeful and non-contingent

— Visual pursuit of mirror or person across midline (most sensitive early sign)

— Localization to noxious stimulus (reaches toward, not just withdraws)

— Command-following even if inconsistent ("squeeze my hand")

— Object recognition or manipulation

— Intelligible verbalization or contingent gestural "yes/no"

— Episodes of tachycardia, hypertension, hyperthermia, diaphoresis, dystonic posturing

— Triggered by stimulation; mimics sepsis or seizure

Key distinction: Withdrawal from pain (flexion away) is reflexive and consistent with VS. Localization (reaching toward the stimulus or trying to remove it) is purposeful and indicates MCS. This single distinction is the highest-yield exam point on the topic.

Coma Recovery Scale–Revised (CRS-R) is the gold-standard bedside tool — 23 items across 6 subscales: auditory, visual, motor, oromotor, communication, arousal.

Findings that confirm VS (wakefulness without awareness):

Findings that confirm MCS (at least one, reproducible):

Emergence from MCS: reliable functional communication or functional object use (e.g., brushes hair with comb).

Hemodynamic/autonomic exam matters because paroxysmal sympathetic hyperactivity (PSH) complicates ~10% of severe TBI DoC:

Check for spasticity, contractures, pressure injuries, heterotopic ossification at hips/elbows — all common and exam-testable complications.

Diagnostic Workup — Initial Labs, Imaging, and Mimic Exclusion

— CBC, CMP, Mg, Phos, Ca (including ionized)

— TSH, free T4 (myxedema can mimic DoC)

— Ammonia, LFTs (hepatic encephalopathy)

— B12, folate, thiamine if nutritional concern

— Drug screen and levels of any sedatives, anticonvulsants, baclofen

— ABG, lactate, cortisol if hemodynamically labile

— MRI brain with DWI, FLAIR, SWI, and DTI is preferred — assesses diffuse axonal injury, brainstem integrity, thalamic damage

— Findings that predict non-recovery: bilateral thalamic injury, dorsolateral brainstem lesions, extensive corpus callosum DAI

— CT acceptable only if MRI contraindicated or for acute change

— Excludes nonconvulsive status epilepticus (a classic Step 3 reversible cause of unresponsiveness)

— Background reactivity and sleep architecture carry prognostic weight

— Burst suppression or generalized suppression after anoxia = poor prognosis

CCS pearl: In a CCS case of a patient "unresponsive 3 weeks after cardiac arrest," your standing orders should include: discontinue sedation, continuous or repeat EEG, MRI brain, TSH, ammonia, B12, medication reconciliation, and neurology consult for CRS-R. Do not order "brain death exam" — that is a different protocol with apnea testing.

The diagnosis of VS/MCS is clinical, but workup is essential to (1) exclude reversible mimics and (2) establish prognosis.

Initial labs — rule out treatable contributors:

Structural imaging:

EEG is mandatory:

Brainstem reflex testing (pupillary, corneal, oculocephalic, gag) distinguishes DoC from brain death — DoC patients retain brainstem reflexes.

Glucose and electrolytes must be normalized before any prognostic statement to family.

Diagnostic Workup — Advanced and Confirmatory Studies

— Task-based fMRI ("imagine playing tennis vs walking through your house") detects cognitive motor dissociation (CMD) — preserved command-following on imaging without behavioral output; present in ~15–20% of clinically "VS" patients

— Resting-state fMRI assesses default mode network integrity

— FDG-PET: preserved frontoparietal metabolism supports MCS or covert consciousness

— Task-based EEG (motor imagery) — cheaper, bedside alternative to fMRI

— Event-related potentials: presence of MMN (mismatch negativity) and P300 suggest intact higher processing

— Perturbational complexity index (PCI) with TMS-EEG — quantifies consciousness; research-grade but increasingly used

— Bilaterally absent N20 cortical responses at 72 hr post-arrest = near-universal non-recovery (when confounders excluded)

— Must be performed off sedation and normothermic

— NSE >60 µg/L at 48–72 hr post–cardiac arrest predicts poor outcome (used in multimodal prognostication, never alone)

Board pearl: In post–cardiac arrest patients, prognostication should be delayed at least 72 hours after return to normothermia and off sedation, and should be multimodal — combine exam (absent pupillary/corneal at ≥72 hr), bilaterally absent N20 SSEPs, malignant EEG, elevated NSE, and diffuse anoxic injury on MRI. Single-modality prognostication is a known cause of premature withdrawal of care.

When bedside exam is ambiguous (suspected covert awareness, family disagreement, prognostic uncertainty), advanced testing is indicated.

Functional neuroimaging:

EEG-based paradigms:

Somatosensory evoked potentials (SSEPs) — strongest single prognostic test after anoxic injury:

Serum biomarkers:

Sleep study/polysomnography: presence of organized sleep architecture (spindles, REM) favors MCS over VS.

Risk Stratification and Prognostic Framework

— Traumatic DoC: substantially better recovery trajectories; meaningful improvement possible up to 12+ months and beyond

— Non-traumatic (anoxic, hemorrhagic): markedly worse; most recovery occurs in first 3 months

— Prefer "chronic VS" with duration stated rather than "persistent" or "permanent"

— Old definitions called VS "permanent" at 3 months (non-traumatic) or 12 months (traumatic), but late recovery is documented and the term "permanent VS" is now discouraged

— Younger age, traumatic etiology, MCS (not VS) at 4 weeks

— Visual pursuit present early

— Preserved EEG reactivity, sleep spindles, P300

— Limited DAI burden on MRI; intact thalamocortical connectivity

— Anoxic etiology, age >65

— Myoclonic status epilepticus in first 24 hr post-arrest

— Bilaterally absent N20 SSEPs (off sedation, normothermic, ≥72 hr)

— Bilateral thalamic or brainstem injury

— Burst suppression or suppressed EEG background

Step 3 management: Use a multimodal, time-adjusted framework: do not deliver a definitive prognosis before 72 hr (anoxic) or 28 days (TBI), avoid the word "permanent," and explicitly counsel families that MCS carries meaningfully better recovery potential than VS — this distinction directly informs goals-of-care discussions.

Two variables dominate prognosis: etiology and time since injury.

Etiology:

Time-based diagnostic terminology (2018 AAN/ACRM/NIDILRR guideline replaced older "persistent" terminology):

Favorable prognostic features:

Unfavorable features:

Cognitive motor dissociation identified on fMRI/EEG predicts higher likelihood of behavioral recovery within 1 year.

Pharmacotherapy — Amantadine and Other Agents

— Adults with traumatic VS or MCS, 4–16 weeks post-injury

— Reduces disability and accelerates functional recovery on DRS

— Start 100 mg PO BID (morning and noon to avoid insomnia)

— Titrate to 200 mg BID by week 3 if tolerated

— Continue 4–6 weeks minimum; reassess

— Lowers seizure threshold — caution post-TBI (high seizure risk)

— Livedo reticularis, peripheral edema, insomnia, agitation, hallucinations

— Renal elimination — dose-reduce when CrCl <50 and avoid or markedly reduce when CrCl <30

— Zolpidem — paradoxical arousal response in a minority (~5%); trial single dose 10 mg and observe

— Modafinil — for arousal; off-label

— Bromocriptine, methylphenidate, levodopa — case-series evidence

— Baclofen (intrathecal) — for severe spasticity, may improve arousal in selected MCS patients

— Sedating antiepileptics (phenobarbital, benzodiazepines)

— Anticholinergics, typical antipsychotics, opioids when avoidable

— These can mask recovery and worsen exam reproducibility

Board pearl: A classic Step 3 stem: TBI patient 6 weeks out, in MCS, on phenytoin and lorazepam, no recovery progress → switch phenytoin to levetiracetam, taper the benzo, and start amantadine 100 mg BID. Document baseline CRS-R and re-score in 4–6 weeks.

Amantadine is the only pharmacologic agent with Level B evidence (2018 AAN guideline) to accelerate recovery in DoC.

Indications:

Dosing:

Mechanism: NMDA antagonist + indirect dopamine agonist → enhances frontostriatal arousal circuitry.

Adverse effects:

Other agents (lower evidence, considered when amantadine fails or contraindicated):

Avoid or minimize:

Rehabilitation Interventions and Neuromodulation

— Medically stable; tracheostomy and PEG acceptable

— Specialized DoC rehab programs (vs standard acute rehab) for patients still in VS/MCS at 4 weeks

— Insurance commonly denies — physician documentation of MCS features (not VS) often changes determinations

— Sensory regulation — structured environmental enrichment; avoid sensory overload

— PT/OT — range-of-motion, splinting, tilt-table to upright posture (improves arousal)

— SLP — oromotor stimulation, swallow assessment, communication device trials (eye-gaze, switch scanning) as MCS deepens

— Sleep-wake regulation — daytime light exposure, melatonin at night

— Tracheostomy and PEG management, capping trials when tolerated

— tDCS (transcranial direct current stimulation) to left DLPFC — modest CRS-R gains in MCS

— Repetitive TMS — investigational

— Deep brain stimulation of central thalamus — research only; case reports of dramatic emergence

— Vagal nerve stimulation — limited case data

— Stretching, splinting, botulinum toxin for focal spasticity

— Oral baclofen, tizanidine (watch sedation)

— Intrathecal baclofen pump for severe generalized spasticity

Step 3 management: When a DoC patient plateaus or insurance pushes for skilled-nursing-facility transfer, document specific MCS behaviors on CRS-R, request specialized DoC rehabilitation, and consider amantadine plus zolpidem trial before accepting "no further benefit from rehab."

Pharmacology alone is insufficient — early, intensive, multidisciplinary rehab is the cornerstone of management.

Inpatient rehabilitation criteria:

Core rehab components:

Neuromodulation (emerging, not first-line):

Spasticity management:

Paroxysmal sympathetic hyperactivity treatment: gabapentin, propranolol, clonidine, low-dose morphine for breakthrough.

Special Populations — Elderly and Renal/Hepatic Impairment

— Lower likelihood of emergence from MCS

— Higher complication rates: aspiration pneumonia, pressure injuries, VTE, delirium superimposed on DoC

— More comorbid cerebrovascular disease lowers reserve

— Polypharmacy magnifies sedation risk — aggressively deprescribe

— CrCl 50–80: standard dosing usually tolerated

— CrCl 30–50: reduce to 100 mg daily

— CrCl 15–29: 100 mg every other day or 200 mg/week

— CrCl <15 or hemodialysis: avoid or 200 mg q7days with careful monitoring

— Accumulation causes confusion, myoclonus, seizures, livedo, NMS-like syndrome

— Amantadine itself is minimally hepatically metabolized — generally safe

— But avoid concurrent sedating agents whose clearance is impaired (benzodiazepines, opioids)

— Watch for hepatic encephalopathy mimicking or worsening DoC — check ammonia

— PEG feeding standard; monitor for refeeding syndrome early on

— Maintain euglycemia — hyperglycemia worsens secondary brain injury

— Vitamin D, calcium for bone health; aggressive DVT prophylaxis

Board pearl: An 82-year-old in VS post–cardiac arrest with CrCl 25: amantadine is not appropriate — minimal benefit in anoxic etiology, accumulation risk, and high seizure risk. The right answer is supportive care, multimodal prognostication, and structured goals-of-care discussion with surrogate, not pharmacologic arousal therapy.

Elderly patients (>65) with DoC have systematically worse outcomes:

Amantadine in renal impairment (high-yield):

Hepatic impairment:

Levetiracetam (preferred AED in DoC) — also renally cleared; dose-adjust for CrCl <80.

Nutrition:

Goals-of-care conversations in elderly DoC patients should occur early and explicitly include time-limited trials (e.g., 3 months of aggressive rehab, then reassess), which align with both evidence and ethical norms.

Special Populations — Pediatrics and Pregnancy

— Most common etiologies: non-accidental trauma, drowning, MVC, cardiac arrest, severe asthma exacerbation with arrest

— Pediatric brains have greater plasticity — recovery trajectories can extend years; avoid early prognostic pessimism

— Use CRS-R Pediatric or Coma/Near-Coma Scale; standard CRS-R items (e.g., functional object use) need developmental adjustment

— Amantadine is used off-label in pediatric TBI DoC (typical 4–6 mg/kg/day divided BID, max 200 mg/day); pediatric neuro-rehab guidance varies

— Mandatory: screen for non-accidental trauma — retinal exam, skeletal survey, social work involvement; mandated reporting applies

— School re-integration planning even in MCS; IEP under IDEA

— Rare but ethically and medically complex (severe TBI, anoxic injury, eclampsia/PRES, AFE, intracranial hemorrhage)

— Continuation of pregnancy in a brain-injured but not brain-dead mother is feasible with multidisciplinary care; involves MFM, neurology, neonatology, ethics

— Avoid amantadine (Category C, limited data) and most arousal agents during pregnancy

— Levetiracetam preferred AED; avoid valproate (teratogenic)

— Anticipate need for decision-making surrogate under state law; document patient's prior wishes when available

Key distinction: Brain death (death by neurologic criteria) is a legal death determination — pregnancy maintenance for fetal viability is a separate, contested decision. DoC (VS/MCS) is not death — the patient is alive, has legal rights, and decisions follow the standard surrogate hierarchy and substituted-judgment standard.

Pediatric DoC:

Pregnancy and DoC:

Adolescents: confidentiality and prior expressed wishes (advance directives, organ donation registry status) often arise — surrogate is usually parent unless emancipated.

Complications and Adverse Outcomes

— Aspiration pneumonia — leading cause of death; mitigated by tracheostomy care, head-of-bed elevation, oral care, swallow rehab

— Atelectasis, mucus plugging, ventilator-associated events

— UTI (chronic catheterization), CLABSI, tracheitis, C. difficile, decubitus ulcer infection, sinusitis from NG tubes

— Very high VTE risk — immobility plus injury; chemoprophylaxis (enoxaparin) once hemorrhage stable, mechanical prophylaxis universally

— Spasticity and contractures — limit ROM, complicate hygiene; treat early

— Heterotopic ossification at hips, elbows, shoulders, knees — present 2–4 months post-injury; treat with NSAIDs (indomethacin), bisphosphonates, ROM, surgical resection if mature

— Osteoporosis, fragility fractures

— Pressure injuries — repositioning q2h, specialty mattress, nutritional optimization (albumin, prealbumin)

— Post-traumatic seizures and epilepsy — risk highest in first year; prophylaxis only first 7 days post-TBI per BTF guideline

— Hydrocephalus (communicating or obstructive) — new decline in arousal, worsening posturing → urgent imaging and VP shunt evaluation

— Paroxysmal sympathetic hyperactivity

CCS pearl: A DoC patient who plateaus then regresses — new decreased arousal, worsening spasticity, vomiting — order non-contrast head CT for hydrocephalus, EEG for NCSE, infectious workup, and medication review before attributing decline to underlying brain injury.

DoC patients are medically fragile — the majority of mortality comes from preventable complications, not the brain injury itself.

Pulmonary:

Infectious:

Thromboembolic:

Musculoskeletal:

Skin:

Neurologic:

GI/nutritional: gastroparesis, GERD, constipation, electrolyte disturbance, malnutrition.

Endocrine: post-TBI hypopituitarism — screen at 3 and 12 months (cortisol, TSH/free T4, IGF-1, gonadotropins).

When to Escalate Care — ICU, Consultation, and Specialized Programs

— Respiratory failure, septic shock, status epilepticus

— Severe PSH refractory to standard agents

— Acute hydrocephalus requiring EVD or shunt revision

— Massive aspiration, airway compromise

— Neurology / neurocritical care — diagnosis, CRS-R, prognostication, AED management

— Physical medicine and rehab (PM&R) — spasticity, rehab planning, amantadine initiation

— Palliative care — early integration improves goals-of-care alignment; palliative care is not synonymous with withdrawal of care

— Ethics committee — disagreements about prognosis, surrogate conflicts, withdrawal decisions

— Speech-language pathology — swallow, communication

— Social work / case management — placement, insurance advocacy

— Patients still in VS/MCS at 4 weeks benefit from referral to dedicated DoC programs (often at academic rehab centers)

— Provide CRS-R serial scoring, advanced imaging access, amantadine/zolpidem trials, family education

— Acute rehab (≥3 hr therapy/day) vs subacute rehab (1–3 hr) vs long-term acute care (LTAC) vs skilled nursing facility

— Document specific MCS features to justify acute rehab placement

Step 3 management: When prognostic disagreement arises between team and family (or among family), the correct next step is a formal interdisciplinary family meeting with palliative care and, if unresolved, an ethics consultation — not unilateral escalation or de-escalation of care. Document substituted-judgment reasoning.

Most DoC patients leave the ICU within weeks; re-escalation is driven by acute medical decompensation, not by the DoC itself.

ICU transfer indications:

Consultations (essential and exam-favored):

Specialized DoC programs:

Triage decisions:

Key Differentials — Other Disorders of Consciousness

— Eyes closed, no sleep-wake cycles, no arousal

— Typically transitions to VS, MCS, or death within 2–4 weeks

— Wakeful (eyes open, sleep-wake cycles) but no awareness

— Only reflexive behaviors; no visual pursuit, no localization, no command-following

— Wakeful with inconsistent but reproducible evidence of awareness

— MCS−: low-level signs (visual pursuit, localization to pain, contingent emotional response)

— MCS+: command-following, intelligible verbalization, or yes/no responses

— Reliable functional communication or functional object use (combs hair with comb, uses cup)

— Often still cognitively impaired (post-traumatic confusional state)

— Bilateral ventral pontine lesion (basilar artery stroke, central pontine myelinolysis)

— Patient is fully aware but quadriplegic and anarthric

— Preserved vertical eye movements and blinking — establish communication via eye code

— EEG shows preserved alpha and sleep architecture

— Bilateral frontal/medial frontal or cingulate damage, or third-ventricle tumor with hydrocephalus

— Wakeful, eyes open, tracks visually, but no spontaneous motor or verbal output

— Distinct from VS by preserved visual tracking with intent

— Absent brainstem reflexes, positive apnea test, irreversible cause — legally dead

Key distinction: Vertical eye movements and blinking in an otherwise unresponsive patient = locked-in syndrome until proven otherwise. Order an MRI to evaluate the pons. Establish communication immediately — these patients are awake.

Distinguishing same-category DoC syndromes is the highest-yield exam content.

Coma:

Vegetative state / UWS:

Minimally conscious state:

Emergence from MCS (eMCS):

Locked-in syndrome (LIS) — frequently misdiagnosed as VS:

Akinetic mutism:

Brain death (death by neurologic criteria):

Key Differentials — Other-Category Mimics

— Wakeful-appearing but unresponsive; subtle eye deviation, lip twitching, automatisms

— Diagnosed by continuous EEG — mandatory in any unexplained DoC

— Treat with benzodiazepine load + AED (levetiracetam, fosphenytoin)

— Hepatic (elevated ammonia), uremic, hypoglycemic, severe hypo/hypernatremia, hypothyroid (myxedema coma), Wernicke's

— Generally reversible with correction

— Benzodiazepines (especially in renal failure with active metabolites), opioids, baclofen withdrawal/toxicity, anticholinergic overload, valproate-induced hyperammonemia without LFT changes

— Always perform medication reconciliation before diagnosing chronic DoC

— Posturing, waxy flexibility, mutism, negativism

— Lorazepam challenge (1–2 mg IV) — dramatic transient improvement is diagnostic

— Treat with benzodiazepines and address underlying psychiatric or medical trigger; ECT for refractory

— Rare in true DoC presentations but considered when imaging and EEG are normal

Board pearl: Any patient labeled "vegetative" who has not had a continuous EEG, complete medication reconciliation, ammonia level, and MRI brain is incompletely worked up. NCSE and medication-induced obtundation are the two reversible diagnoses most often missed on Step 3 stems.

Mimics outside the DoC spectrum are exam favorites because they are reversible if recognized.

Nonconvulsive status epilepticus (NCSE):

Toxic-metabolic encephalopathy:

Sedative/medication effect:

Catatonia:

Severe depression / conversion disorder / malingering:

Post-ictal state — prolonged after status epilepticus

Central nervous system infection — meningoencephalitis, autoimmune encephalitis (anti-NMDA receptor) — treatable; check CSF, autoimmune panel

PRES, basilar migraine, transient global amnesia — usually transient

Severe sleep deprivation or ICU delirium — fluctuating, not persistent

Long-Term Plan, Discharge Planning, and Goals of Care

— Acute inpatient rehab with DoC program — preferred for MCS or evolving VS in first months

— LTAC — for patients still vent/trach-dependent but medically complex

— Skilled nursing facility — long-term custodial with limited therapy

— Home with services — uncommon but possible with strong family caregiver, hospital bed, suction, PEG, hospice or home health

— Amantadine if traumatic etiology, ongoing benefit

— Levetiracetam if seizure history (avoid prolonged "prophylaxis" past 7 days post-TBI without indication)

— Baclofen (oral or intrathecal) for spasticity

— PPI, bowel regimen, DVT prophylaxis (enoxaparin or apixaban long-term if persistently immobile)

— Vitamin D, calcium, multivitamin

— Melatonin for sleep-wake regulation

— Confirm advance directive / POLST / surrogate documentation

— Establish code status explicitly (full code, DNR, DNI, comfort-focused)

— Tracheostomy and PEG care education

— Seizure precautions and rescue plan

— Pressure injury prevention plan

— Follow-up: PM&R, neurology, primary care, specialty as needed

— Use substituted judgment (what would the patient want?) over best-interest when prior wishes are known

— Frame time-limited trials (e.g., 3-month aggressive rehab, then reassess CRS-R and goals)

— Hospice eligibility if goals shift to comfort

Step 3 management: Every DoC discharge order set should include (1) explicit code status documented, (2) named surrogate decision-maker, (3) seizure rescue plan, (4) VTE prophylaxis, (5) skin and bowel regimens, (6) outpatient PM&R follow-up within 2–4 weeks, and (7) communication of diagnosis and prognosis to the receiving facility in writing.

Disposition depends on DoC severity, family resources, insurance, and goals of care.

Disposition options:

Standing chronic medications:

Discharge checklist (CCS-style):

Goals-of-care framework:

Follow-Up, Monitoring Parameters, and Family Support

— Repeat weekly during acute rehab, then monthly for first year, then every 3–6 months

— Detect transition from VS → MCS → eMCS

— Document specific behaviors to support level-of-care decisions and insurance appeals

— MRI brain at 3 and 6–12 months if clinical change, to assess atrophy, hydrocephalus, new lesions

— Urgent CT for acute decline (rule out hydrocephalus, hemorrhage, infarct)

— Screen at 3 and 12 months: morning cortisol, TSH/free T4, IGF-1, FSH/LH/testosterone or estradiol, prolactin

— Replace deficiencies; untreated adrenal insufficiency mimics DoC worsening

— Caregiver burden screening — high rates of depression, anxiety, financial strain

— Connect to Brain Injury Association of America, local support groups

— Respite care planning

— Counseling on prognostic uncertainty — avoid both false hope and premature pessimism

— Re-explore goals of care at each major transition (rehab → SNF → home, or with each medical setback)

Board pearl: Counsel families that CRS-R scores can fluctuate by 2–3 points day-to-day due to arousal, fatigue, medication, or infection — a single low score does not define the ceiling. Serial assessment under optimal conditions is the gold standard for tracking recovery.

Serial CRS-R assessments are the cornerstone of longitudinal monitoring:

Imaging follow-up:

Endocrine surveillance (post-TBI hypopituitarism):

Bone health: DEXA at 1 year; vitamin D level; consider bisphosphonate if osteoporosis or recurrent fragility fracture.

Nutrition: weight, albumin/prealbumin, electrolytes monthly initially.

Spasticity review every 3 months; consider botulinum toxin or ITB pump escalation.

Family and caregiver support (exam-favored, often underweighted):

Driving, work, capacity: not applicable until eMCS with sustained cognitive recovery; formal neuropsych evaluation required.

Ethical, Legal, and Patient Safety Considerations

— Healthcare proxy / DPOA → spouse → adult children (majority) → parents → siblings → other relatives → close friend

— Apply substituted judgment first (what would patient want?), then best interest if wishes unknown

— Legally and ethically permissible at any point if consistent with patient wishes or best interest

— Artificial nutrition and hydration is legally considered medical treatment (Cruzan v. Director, Schiavo) and may be withdrawn

— Requires careful documentation, family meetings, palliative care involvement

— Avoid the word "permanent" in the first months — well-documented late recoveries

— Avoid self-fulfilling prophecy: early withdrawal based on incomplete prognostic data drives outcomes

— Multimodal, time-delayed (≥72 hr off sedation) prognostication is the safety standard, especially post–cardiac arrest

— DoC patient cannot consent — surrogate consents for procedures (PEG, tracheostomy, shunt)

— Research participation requires surrogate consent + IRB-approved DoC-specific protections

Step 3 management: When a family asks "Is there any chance she'll wake up?" within the first weeks after anoxic injury, the correct response is honest acknowledgment of uncertainty, commitment to multimodal prognostication at ≥72 hr off sedation, and a scheduled follow-up meeting — not a definitive yes or no.

DoC sits at the center of medical ethics — surrogate decision-making, withdrawal of life-sustaining treatment, and resource allocation.

Surrogate decision-making hierarchy (varies by state; common order):

Withdrawal of life-sustaining treatment:

Prognostic communication safety:

Informed consent edge cases:

Organ donation: not applicable in VS/MCS (patient is alive); becomes relevant only if brain death later occurs or if cardiac death after withdrawal (DCD).

Mandatory reporting: pediatric DoC from suspected abuse triggers CPS report; adult abuse/neglect triggers APS report (state-dependent).

Transition-of-care safety: handoff between hospital → rehab → SNF is the highest-risk moment; written communication of DoC level (VS vs MCS), code status, surrogate, seizure plan, and medications prevents medication errors and inappropriate resuscitation.

High-Yield Associations and Rapid-Fire Facts

Board pearl: If a stem mentions "tracks people with eyes across the room" or "cries when daughter enters" — even once — the answer is MCS, not VS, and management pivots toward specialized DoC rehab, amantadine (if traumatic), and continued aggressive intervention.

VS = wakefulness without awareness; MCS = inconsistent but reproducible awareness.

Visual pursuit = earliest and most reliable sign of MCS.

Localization to pain = MCS; withdrawal from pain = VS.

Coma rarely lasts >4 weeks — evolves to VS, MCS, or death.

Misdiagnosis rate of VS ~40% with informal exam; CRS-R is gold standard.

Cognitive motor dissociation: ~15–20% of clinically "VS" patients show command-following on fMRI/EEG.

Amantadine — only Level B drug; traumatic DoC, 4–16 weeks post-injury, 100–200 mg BID.

Zolpidem paradoxical response in ~5% — worth a trial dose.

Bilaterally absent N20 SSEPs at ≥72 hr post-arrest = poor prognosis (off sedation, normothermic).

NSE >60 µg/L at 48–72 hr post-arrest = poor prognosis.

Term "permanent VS" is discouraged (2018 AAN guideline) — use "chronic VS" with duration.

Locked-in syndrome: bilateral ventral pontine lesion; preserved vertical eye movements; patient is awake.

Brain death ≠ VS — brain death is legal death; VS/MCS patients are alive.

Post-traumatic seizure prophylaxis: only first 7 days post-TBI (levetiracetam or phenytoin).

Hydrocephalus — consider in any DoC patient with new decline; treat with VP shunt.

Heterotopic ossification appears 2–4 months post-injury at hips/elbows; treat with NSAIDs, bisphosphonates, ROM.

Paroxysmal sympathetic hyperactivity — gabapentin, propranolol, clonidine first-line.

Post-TBI hypopituitarism — screen at 3 and 12 months.

Artificial nutrition/hydration is medical treatment and may be withdrawn (Cruzan, Schiavo).

Mandatory CPS reporting for pediatric DoC from suspected non-accidental trauma.

Board Question Stem Patterns

— 28-year-old, 6 weeks after MVC with severe TBI, eyes open with sleep-wake cycles, occasionally tracks his mother across the room, otherwise unresponsive. Next step? → Diagnose MCS, refer to specialized DoC rehab, initiate amantadine 100 mg BID.

— 55-year-old with basilar artery stroke, "appears unresponsive" on exam but family reports she blinks "yes/no" to questions. Next step? → Vertical eye movement assessment, MRI of pons, establish blink-based communication — diagnosis is locked-in syndrome, not VS.

— 70-year-old in nursing home, "vegetative" for 3 weeks after hospitalization for UTI, intermittent eye deviation. Next step? → Continuous EEG → diagnose NCSE → treat with benzodiazepine and AED.

— 60-year-old, 36 hours post–cardiac arrest, family asks about withdrawal of care. Next step? → Defer definitive prognosis ≥72 hr off sedation and normothermic; obtain multimodal assessment (exam, SSEPs, EEG, MRI, NSE); meanwhile continue full support.

— 35-year-old TBI patient, 8 weeks post-injury, in MCS, plateaued in rehab. Next best pharmacologic step? → Amantadine 100 mg BID, titrate to 200 mg BID.

— Spouse wants withdrawal; adult son objects; no advance directive. Next step? → Interdisciplinary family meeting with palliative care; if unresolved, ethics consultation; substituted judgment standard.

— Stable 6-month post-anoxic VS patient becomes more obtunded, with new vomiting and worsening spasticity. Next step? → Head CT to evaluate hydrocephalus, EEG for NCSE, infection workup.

— 4-month-old in VS after "fall from couch," retinal hemorrhages on exam. Next step? → Skeletal survey, social work, mandated CPS report.

Step 3 management: Read DoC stems for (1) exact duration since injury, (2) etiology (TBI vs anoxic), (3) presence of any purposeful behavior, and (4) medication list for sedatives — those four data points determine nearly every correct answer.

Pattern 1 — VS vs MCS distinction:

Pattern 2 — Locked-in misdiagnosis:

Pattern 3 — Reversible mimic (NCSE):

Pattern 4 — Premature prognostication:

Pattern 5 — Amantadine selection:

Pattern 6 — Surrogate conflict:

Pattern 7 — New decline in chronic VS:

Pattern 8 — Pediatric non-accidental trauma:

One-Line Recap

Disorders of consciousness sit on a clinical spectrum where the vegetative state shows wakefulness without awareness, the minimally conscious state shows inconsistent but reproducible awareness (especially visual pursuit or localization), and management hinges on rigorous CRS-R-based diagnosis, exclusion of reversible mimics, multimodal time-delayed prognostication, amantadine for traumatic DoC at 4–16 weeks, specialized rehabilitation, prevention of medical complications, and ethically grounded surrogate decision-making.

Board pearl: The single highest-yield distinction on this topic is VS vs MCS — and the single highest-yield bedside sign that flips the diagnosis is reproducible visual pursuit. Spot it, document it, and the management plan changes.

Diagnosis: CRS-R is gold standard; informal bedside exam misdiagnoses ~40%. Visual pursuit and localization define MCS — they change prognosis and management.

Workup: Rule out NCSE (EEG), metabolic and medication causes, hydrocephalus (imaging), and post-TBI hypopituitarism; MRI for structural prognostication; SSEPs and NSE for anoxic prognostication ≥72 hr off sedation.

Treatment: Amantadine 100–200 mg BID is the only Level B drug (traumatic etiology, 4–16 weeks post-injury); pair with intensive multidisciplinary rehab; deprescribe sedating medications; manage spasticity, PSH, and seizures (AED only first 7 days post-TBI as prophylaxis).

Ethics and safety: Avoid the word "permanent"; use multimodal prognostication; honor substituted judgment via surrogate; artificial nutrition is withdrawable medical treatment; mandatory reporting applies in suspected pediatric abuse; protect transitions of care with explicit code status, surrogate, and seizure-plan documentation.